Evidence map›Paper›PMID 34021431›Full record

ArticleCell biology and toxicology2022

Stimulation of de novo glutathione synthesis by nitrofurantoin for enhanced resilience of hepatocytes.

Lukas S Wijaya, Carina Rau, Theresa S Braun, Serif Marangoz, Vincent Spegg, Matthijs Vlasveld, Wiebke Albrecht, Tim Brecklinghaus, Hennicke Kamp, Joost B Beltman and 4 more

Open access · hybridAbstract read
In one paragraph

Article in Cell biology and toxicology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.7field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 12 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 4 institutions in 2 countries.

Lukas S WijayaDivision of Drug Discovery and Safety, Leiden Academic Centre for Drug Research, Leiden University, 2300, RA, Leiden, The Netherlands.
Carina RauIn vitro Toxicology and Biomedicine, Department of Biology, University of Konstanz, P.O. Box M657, Universitätsstr. 10, 78457, Konstanz, Germany.
Theresa S BraunKonstanz Research School Chemical Biology (KoRS-CB), Department of Chemistry, University of Konstanz, 78457, Konstanz, Germany.
Serif MarangozIn vitro Toxicology and Biomedicine, Department of Biology, University of Konstanz, P.O. Box M657, Universitätsstr. 10, 78457, Konstanz, Germany.
Vincent SpeggIn vitro Toxicology and Biomedicine, Department of Biology, University of Konstanz, P.O. Box M657, Universitätsstr. 10, 78457, Konstanz, Germany.
Matthijs VlasveldDivision of Drug Discovery and Safety, Leiden Academic Centre for Drug Research, Leiden University, 2300, RA, Leiden, The Netherlands.
Wiebke AlbrechtLeibniz Research Centre for Working Environment and Human Factors, Technical University Dortmund, Dortmund, Germany.
Tim BrecklinghausLeibniz Research Centre for Working Environment and Human Factors, Technical University Dortmund, Dortmund, Germany.
Hennicke KampBASF SE, Experimental Toxicology and Ecology, Ludwigshafen am Rhein, Germany.
Joost B BeltmanDivision of Drug Discovery and Safety, Leiden Academic Centre for Drug Research, Leiden University, 2300, RA, Leiden, The Netherlands.
Jan G HengstlerLeibniz Research Centre for Working Environment and Human Factors, Technical University Dortmund, Dortmund, Germany.
Bob van de Water *Division of Drug Discovery and Safety, Leiden Academic Centre for Drug Research, Leiden University, 2300, RA, Leiden, The Netherlands.
Marcel Leist *In vitro Toxicology and Biomedicine, Department of Biology, University of Konstanz, P.O. Box M657, Universitätsstr. 10, 78457, Konstanz, Germany.
Stefan Schildknecht *In vitro Toxicology and Biomedicine, Department of Biology, University of Konstanz, P.O. Box M657, Universitätsstr. 10, 78457, Konstanz, Germany. Stefan.Schildknecht@uni-konstanz.de.ORCID 0000-0001-9824-4991
University of Konstanz · DELeiden University · NLTU Dortmund University · DEBASF (Germany) · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Toxicity is not only a function of damage mechanisms, but is also determined by cellular resilience factors. Glutathione has been reported as essential element to counteract negative influences. The present work hence pursued the question how intracellular glutathione can be elevated transiently to render cells more resistant toward harmful conditions. The antibiotic nitrofurantoin (NFT) was identified to stimulate de novo synthesis of glutathione in the human hepatoma cell line, HepG2, and in primary human hepatocytes. In intact cells, activation of NFT yielded a radical anion, which subsequently initiated nuclear-factor-erythroid 2-related-factor-2 (Nrf2)-dependent induction of glutamate cysteine ligase (GCL). Application of siRNA-based intervention approaches confirmed the involvement of the Nrf2-GCL axis in the observed elevation of intracellular glutathione levels. Quantitative activation of Nrf2 by NFT, and the subsequent rise in glutathione, were similar as observed with the potent experimental Nrf2 activator diethyl maleate. The elevation of glutathione levels, observed even 48 h after withdrawal of NFT, rendered cells resistant to different stressors such as the mitochondrial inhibitor rotenone, the redox cycler paraquat, the proteasome inhibitors MG-132 or bortezomib, or high concentrations of NFT. Repurpose of the antibiotic NFT as activator of Nrf2 could thus be a promising strategy for a transient and targeted activation of the endogenous antioxidant machinery. Graphical abstract.

Indexed as

Glutamate-Cysteine LigaseNF-E2-Related Factor 2Anti-Bacterial AgentsAntioxidantsBortezomibGlutathioneHepatocytesHumansNitrofurantoinOxidative StressParaquatProteasome InhibitorsRNA, Small InterferingRotenoneAnti-Bacterial AgentsAntioxidantsBortezomibGlutamate-Cysteine LigaseGlutathioneNF-E2-Related Factor 2NitrofurantoinParaquatProteasome InhibitorsRNA, Small InterferingRotenoneCytochrome P450 reductaseGlutathioneHepatocytesNitrofurantoinNrf2

Identifiers

PMID34021431
PMCPMC9525367
OpenAlexW3161539765

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.